

8th International Symposium on Childhood, Adolescent and Young Adult Non-Hodgkin Lymphoma

September 26-28, 2025

New York City, NY, USA

The InterContinental
New York Times Square

Hosted By:

Mitchell S. Cairo, MD - Chair

**Chief, Pediatric Hematology, Oncology
and Stem Cell Transplantation**

**Professor of Pediatrics, Medicine, Pathology,
Microbiology & Immunology
and Cell Biology & Anatomy**

Director, WMC Cancer Center

Maria Fareri Children's Hospital

Westchester Medical Center (WMC)

New York Medical College (NYMC)



SCHEDULE AT A GLANCE

Chair: Mitchell S. Cairo, MD, USA	Friday, September 26, 2025	Saturday, September 27, 2025	Sunday, September 28, 2025
<p>International Scientific Committee & Faculty</p> <p>Sarah Alexander, MD Carl Allen, MD, PhD Shifra Ash, MD, BSc AndisheAttarbaschi,MD Anthony Audino, MD Matthew Barth, MD Auke Beishuizen, MD, PhD Catherine Bollard, MD Amos Burke, MD Birgit Burkhardt, MD, PhD Shanmuganathan Chandrakasan,MD Alan KS Chiang, MD,PhD Roberto Chiarle, MD Christine Damm-Welk, PhD Alan Davidson, MD Yanlong Duan, MD Matthew Ehrhardt, MD Kojo Elenitoba-Johnson, MD, PhD Ronit Elhasid, MD Nader El-Mallawany, MD Andrew Evens, DO Allyson Flower, MD J. Kimble Frazer, MD, PhD Paul Galardy, MD Stanton Goldman, MD Thomas Gross, MD, PhD Ian Hann, MD Paul Harker-Murray, MD, PhD Robert Hayashi, MD Michelle Hermiston, MD, PhD Jessica Hochberg, MD David Hoogstra, MD Steven Horwitz, MD Wolfram Klapper, MD Ryoji Kobayashi, MD,PhD Yuki Koga, MD,PhD M. Tezer Kutluk, MD, PhD Margaret Lamb, MD Vasiliki Leventaki, MD Megan Lim, MD, PhD Michael Link, MD Jan Loeffen, MD, PhD Eric Lowe, MD Britta Maecker-Kolhoff, MD Shannon Maude, MD, PhD Christine Mauz-Koerholz, MD, PhD Friederike Meyer-Wentrup, MD Rodney Miles, MD, PhD Jordan Milner, MD Veronique Minard-Colin, MD, PhD Lara Mussolin, PhD Ilske Oschlies, MD Sherrie Perkins, MD, PhD Marta Pillon,MD LeticiaQuintanilla-Fend, MD Vikki Rand, PhD Susan Rheingold, MD Charlotte Rigaud, MD, PhD Lisa Giulino-Roth, MD Itziar Salaverria, PhD Julia Salmeron-Villalobos, PhD Barbara Savoldo, MD, PhD Masashiro Sekimizu, MD, PhD Reiner Siebert, MD Filippo Spreafico, MD Christian Steidl, MD</p>	<p>7:00 AM - 6:00 PM Registration and Poster Set-up</p>	<p>7:00 AM - 5:00 PM Registration</p>	<p>7:00 AM – 8:30 AM Registration</p>
	<p>Opening Ceremony 8:00 – 8:15 AM</p>	<p>Breakfast Symposium Sponsored by Jazz Pharmaceuticals 7:00 – 7:45 AM</p>	<p>Breakfast Symposium Sponsored by Servier Pharmaceuticals 7:00 – 7:45 AM</p>
	<p>The Angelo Rosolen, MD Memorial Lecture 8:20 – 9:00 AM</p>	<p>Meet the Professors 7:45 – 8:30 AM</p>	<p>Meet the Professors 7:45 – 8:30 AM</p>
	<p>Plenary Session I Mature B-Cell NHL 9:00 – 10:45 AM</p>	<p>Plenary Session V Lymphoma HSCT, Cell Therapy & Immunology 8:30 – 10:15 AM</p>	<p>Plenary Session IX Best Oral Abstracts 8:30 – 10:00 AM</p>
	<p>Coffee Break 10:45 – 11:05 AM</p>	<p>Coffee Break 10:15 – 10:45 AM</p>	<p>Coffee Break 10:00 – 10:15 AM</p>
	<p>Plenary Session II Lymphoma Translational Biology (Dedicated to Warren Sanger, PhD) 11:05 – 12:30 PM</p>	<p>Plenary Session VI Mature NK/TT-Cell Non Hodgkin Lymphoma 10:45 – 12:30 PM</p>	<p>Plenary Session X Lymphoblastic Lymphoma & ALCL 10:15 – 12:15 PM</p>
	<p>Lunch Symposium Sponsored by Amgen, Inc. 12:45 – 1:30 PM</p>	<p>Lunch Symposium Sponsored by Sobi 12:45 – 1:30 PM</p>	<p>Award Session Best Oral Abstract, Best Poster Discussion Abstract, & Best Poster Abstract 12:15 – 12:25 PM</p>
	<p>Plenary Session III Immunodeficiency Associated and Other Rare Lymphomas 1:30 – 3:15 PM</p>	<p>Plenary Session VII Novel Therapeutics 1:30 – 3:15 PM</p>	<p>Closing Remarks 12:25 – 12:30 PM</p>
	<p>Coffee Break 3:15 – 3:45 PM</p>	<p>Coffee Break 3:15 – 3:40 PM</p>	<p>Jaroslav Sterba, MD, PhD Jan Styczynski, MD Ritsuro Suzuki, MD, PhD David Teachey, MD Suzanne Turner, PhD Anne Uyttbroeck, MD, PhD TimurValiev, MD, PhD Birte Wistinghausen, MD Wilhelm Woessmann, MD Ana Xavier, MD Yonghong Zhang, MD, PhD Alfred Reiter, MD Chair Emeritus Catherine Patte, MD, Emeritus</p>
	<p>Plenary Session IV Adolescent and Young Adult Lymphoma 3:45 – 5:30 PM Supported by The Leukemia & Lymphoma Society</p>	<p>Plenary Session VIII Poster Discussion 3:40 – 6:30 PM</p>	
	<p>Welcome Reception & Poster Viewing 5:30 – 6:45 PM</p>	<p>Take Down Posters 6:30 PM</p>	

Friday, September 26, 2025

- 7:00 AM – 6:00 PM** **REGISTRATION and POSTERSET-UP**
- 7:00 – 8:00 AM** **CONTINENTAL BREAKFAST**
- 8:00 – 8:15 AM** **OPENING CEREMONY**
Mitchell S. Cairo, MD, CHAIR, USA
- 8:15 – 8:20 AM** **THE PERSPECTIVES FOR THE GLOBAL INITIATIVE FOR CHILDHOOD CANCER**
Guillermo Chantada, MD, PhD, Spain
- 8:20 – 9:00 AM** **THE ANGELO ROSOLEN, MD MEMORIALLECTURESHIP**
- 8:20 – 8:25 AM** **INTRODUCTION OF ANGELO ROSOLEN,MD AWARD**
Marta Pillon, MD, Italy
Lara Mussolin, PhD, Italy
- 8:25 – 8:35 AM** **INTRODUCTION OF MITCHELL S. CAIRO, MD,USA**
Alfred Reiter, MD
Professor Emeritus, University of Giessen, Germany
- 8:35 – 9:00 AM** **CHEMORADIOTHERAPY FREE TREATMENT OF PEDIATRIC MATURE B CELL LYMPHOMA:
CAN WE ACHIEVE THIS IN THE NEAR FUTURE?**
Mitchell S. Cairo, MD, USA
- 9:00 – 10:45 AM** **PLENARY SESSION I - MATURE B-CELL NHL**
Moderators:
Sarah Alexander, MD, Canada
Veronique Minard-Colin, MD, PhD, France
Stanton Goldman, MD, USA
- 9:00 – 9:20 AM** **SINGLE-CELL TRANSCRIPTOMICS OF PEDIATRIC BURKITT LYMPHOMA REVEALS INTRA-
TUMOR HETEROGENEITY AND MARKERS OF THERAPY RESISTANCE**
Lara Mussolin, PhD, Italy
- 9:20 – 9:40 AM** **NOVEL PATHOGENETIC MECHANISMS IN PEDIATRIC DIFFUSE LARGE B CELL
LYMPHOMA**
Keynote Speaker #1 - Kojo Elenitoba-Johnson, MD, PhD, USA
- 9:40 – 10:00 AM** **POLATUZUMAB-VEDOTIN IN MATURE B-NHL**
Anthony Audino, MD, USA
- 10:00 – 10:15 AM** **Summary of the efficacy of China Net Childhood Lymphoma-mature B-cell lymphoma-
2017 regimen in the treatment of pediatric Burkitt's lymphoma: A Multicenter Clinical
Report from China**
Zhang Meng^{1#}, Wang Hongsheng^{2#}, Jin Ling¹, Yang Jing¹, Huang Shuang¹, Nan Li¹, Liu Ying³,
Hu Bo³, Wu Pan⁴, Zheng Mincui⁴, Li Fu⁵, Yang Xiaomei⁵, Liu Ansheng⁶, Qin Shuang⁶, Yuan
Xiaojun⁷, Dong Yushuang⁷, Liu Wei⁸, Zhou Jianwen⁸, Zhang Leping⁹, Jia Yueping⁹, Wang

Jian¹⁰, Qu Lijun¹⁰, Dai Yunpeng¹¹, Guan Guotao¹¹, Sun Lirong¹², Jiang Jian¹², Liu Rong¹³, Jin Runming¹⁴, Wang Zhujun¹⁴, Wang Xige¹⁵, Zhang Baoxi¹⁶, Chen Kailan¹⁷, Zhou Chunju¹⁸, Gao Zifen¹⁹, Zhai Xiaowen², **Duan Yanlong**¹, Zhang Yonghong¹

¹Medical Oncology Department, Pediatric Oncology Center, Beijing Children's Hospital, Capital Medical University, National Center for Children's Health, Beijing Key Laboratory of Pediatric Hematology Oncology, Key Laboratory of Major Diseases in Children, Ministry of Education, Beijing 100045, China; ²Department of Hematology, National Children's Medical Center, Children's Hospital of Fudan University, Shanghai 201102, China; ³Department of Pediatric Lymphoma, Beijing GoBroad Boren Hospital, Beijing 100070, China; ⁴Department of Hematology, Hunan Children's Hospital, Changsha 410007, China; ⁵Hematology & Oncology Department, Children's Hospital Affiliated to Shandong University, Jinan 250022, China; ⁶Department of Hematology & Oncology, Xi'an Children's Hospital, Xi'an 710002, China; ⁷Department of Pediatric Hematology / Oncology, Xinhua Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200092, China; ⁸Department of Hematology & Oncology, Zhengzhou Children's Hospital, Zhengzhou 450018, China; ⁹Department of Pediatrics, Peking University People's Hospital, Beijing 100044, China; ¹⁰Department of Hematology & Oncology, Anhui Children's Hospital, Hefei 230022, China; ¹¹Department of Pediatric Hematology & Endocrinology, Shandong Provincial Hospital affiliated to Shandong University, Jinan 250021, China; ¹²Department of Pediatric Hematology & Oncology, The Affiliated Hospital of Qingdao University, Qingdao 266003, China; ¹³Department of Hematology, Children's Hospital affiliated to Capital Pediatric Research Institute, Beijing 100020, China; ¹⁴Department of Pediatrics, Union Hospital, Tongji Medical College, Huazhong University, Wuhan 430022, China; ¹⁵Department of Hematology & Oncology, Third Affiliated Hospital of Zhengzhou University, Zhengzhou 450052; ¹⁶Department of Pediatrics, Second Hospital of Hebei Medical University, Shijiazhuang 050004, China; ¹⁷Department of Hematology & Oncology, Wuhan Children's Hospital, Tongji Medical College, Huazhong University of Science & Technology, Wuhan 430016, China; ¹⁸Pathology Department, Beijing Children's Hospital, Capital Medical University, National Center for Children's Health, Beijing 100045, China; ¹⁹Department of Pathology, Peking University Third Hospital, Beijing 100191, China. *co-first authors

10:15 – 10:30 AM

Is Transcriptional Cell State the Key to Predicting Resistance in Burkitt Lymphoma?

Christopher Steel¹, Callum Malcolm¹, Dawid Przystupski², Jamie Matthews¹, Emily James¹, Quiyu Lian⁶, Ashley Nicholls³, Kirsty Sawicka³, Ian Cannell³, Marketa Rackova⁴, G.A. Amos Burke⁵, Ben D. Simons⁶, and Suzanne D. Turner^{1,7}

¹Department of Pathology, University of Cambridge, Cambridge, United Kingdom;

²Department of Paediatric Bone Marrow Transplantation, Oncology and Haematology, Wroclaw Medical University, Poland; ³Cancer Research UK Cambridge Institute, University of Cambridge, Li Ka Shing Centre, Robinson Way, Cambridge, United Kingdom; ⁴Department of Pediatric Hematology and Oncology, Second Faculty of Medicine, Charles University and University Hospital Motol, Prague, Czech Republic; ⁵Cancer Research UK Clinical Trial Unit, School of Medical Sciences, College of Medicine and Health, University of Birmingham, UK;

⁶Wellcome Trust, Cancer Research UK Gurdon Institute, University of Cambridge, Cambridge, United Kingdom; ⁷Faculty of Medicine, Masaryk University, Brno, Czechia.

10:30 – 10:45 AM

CD20-Negative Relapsed/Refractory Mature B-Cell Non-Hodgkin Lymphoma (B-NHLs) and Mature B-Cell Leukemia in Children, Adolescent and Young Adults: A Retrospective Review

Luciana Vinti¹, Jolanda Pianese¹, Daniela Onofrillo², Irene D'Alba³, Raffaella De Santis⁴, Veronica Barat⁵, Elisabetta Schiavello⁶, Paola Muggeo⁷, Concetta Micalizzi⁸, Katia Perruccio⁹, Valentina Bertaina¹, Lara Mussolin¹⁰, Elisa Carraro¹⁰, Marta Pillon¹⁰, Barbara Buldini¹⁰, Rita De Vito¹, Franco Locatelli¹

¹*Ospedale Pediatrico Bambino Gesù, Roma, Italy*; ²*Civile Santo Spirito, Pescara, Italy*;

³*Ospedale Salesi, Ancona, Italy*; ⁴*Ospedale Casa Sollievo della Sofferenza, San Giovanni Rotondo, Italy*; ⁵*AOU Città della Salute e della Scienza, Torino, Italy*; ⁶*Fondazione IRCCS Istituto Nazionale Tumori, Milano, Italy*; ⁷*Ospedale Giovanni XXIII, Bari, Italy*; ⁸*Ospedale Gianina Gaslini, Genova, Italy*; ⁹*Ospedale SM Misericordia, Perugia, Italy* ¹⁰*Azienda Ospedaliera- Università degli Studi, Padova, Italy*.

10:45 – 11:05 AM

COFFEEBREAK

11:05 – 12:30 PM

PLENARY SESSION II - LYMPHOMA TRANSLATIONAL BIOLOGY (DEDICATED TO WARREN SANGER, PhD)

Moderators:

Lara Mussolin, PhD, Italy

Megan Lim, MD, PhD, USA

11:05 – 11:25 AM

MOLECULAR HETEROGENEITY IN PEDIATRIC ALK+ ALCL

Vasiliki Leventaki, MD, USA

11:25 – 11:45 AM

NOTCH 1 FUSIONS AND CLONAL EVOLUTION IN CHILDHOOD-T-LYMPHOBLASTIC LYMPHOMA

Birgit Burkhardt, MD, PhD, Germany

11:45 – 12:00 PM

MicroRNAs Downregulate Tumor Suppressor GRK2 in MALT1-Dependent Diffuse Large B-Cell Lymphoma

Jing Cheng^{1,7}, Mei Smyers¹, Matt Trotta¹, Neil M Carleton^{2,3}, Lisa M Maurer¹, Uma Chandran^{4,5}, Min Xia⁶, Ari M Melnick⁶, Peter C Lucas^{2,5,7,8}, Linda M McAllister-Lucas^{1,5,7,8,9}

¹*Department of Pediatrics and* ²*Department of Pathology, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA*; ³*Medical Scientist Training Program, University of Pittsburgh-Carnegie Mellon University, Pittsburgh, PA, USA*; ⁴*Department of Biomedical Informatics, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA*; ⁵*UPMC Hillman Cancer Center, Pittsburgh, PA, USA*; ⁶*Department of Medicine, Weill Cornell Medical College, New York, NY, USA*; ⁷*Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA*; ⁸*Mayo Clinic Comprehensive Cancer Center, Mayo Clinic, Rochester, MN, USA*; ⁹*Department of Pediatrics, Mayo Clinic, Rochester, MN, USA*.

12:00 – 12:15 PM

Extracellular Vesicles as Key Orchestrators of Bone Marrow Niche Remodeling in Pediatric Mature B-Cell Acute Lymphoblastic Leukemia

C.C. Damanti^{1,2}, A. Cani^{1,2}, E. Gaffo³, S. Bortoluzzi³, Alessia Danieli^{1,2}, E. Carraro¹, L. Vinti⁴, A. Sala⁵, A. Biffi¹, M. Pillon¹, S. Bresolin^{1,2}, L. Mussolin^{1,2}

¹*Maternal and Child Health Department, University of Padova, Padova, Italy*; ²*Istituto di Ricerca Pediatrica Città della Speranza, Padova, Italy*; ³*Department of Molecular Medicine, University of Padova, Padova, Italy*; ⁴*IRCCS Ospedale Pediatrico Bambino Gesù and Sapienza University of Rome, Rome, Italy*; ⁵*Pediatrics, Fondazione IRCCS San Gerardo Dei Tintori, Monza, Italy*.

12:15 – 12:30 PM

High Resolution Architecture of *IRF4* Rearrangements in Children and Adults

Ariadna Colmenero^{1,2}, Leonie Frauenfeld^{1,2,3}, Sara Mato^{1,2}, Ferran Nadeu^{1,4}, Julia Salmeron-Villalobos¹, Joan Enric Ramis-Zaldivar^{1,4}, Anna Montaner¹, Natalia Castrejón de Anta^{2,5}, Blanca Gonzalez-Farre^{2,4,5}, Noelia García¹, Vicente Arredondo³, Jaime Verdú-Amorós^{4,6}, Mara Andrés⁷, Maitane Andiñ⁸, Daniel Azorín⁹, Verónica Celis¹⁰, Socorro María Rodríguez-Pinilla¹¹, Eric D Hsi¹², Gabriela Gheorghe¹³, Rachel Mariani¹⁴, Kristian Schafernak¹⁴, Anna Shestakova¹⁵, Madhu P Menon¹⁵, Francisco J Llamas Gutierrez¹⁶, Konnie Hebeda¹⁷, Tapan Bhavsar¹⁸, Armando Lopez-Guillermo⁵, Elaine S. Jaffe¹⁹, Leticia Quintanilla-Martínez³, Elías Campo^{1,4,5}, Olga Balagué^{1,4,5}, Itziar Salaverria^{1,4}

¹*Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain;*

²*University of Barcelona (UB), Barcelona, Spain;* ³*University Hospital and Comprehensive Cancer Center Tübingen, Institute of Pathology and Neuropathology, Tübingen, Germany;*

⁴*Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain;*

⁵*Hematopathology Section, Laboratory of Pathology, Hospital Clinic de Barcelona, Barcelona, Spain;* ⁶*Pediatric Oncology Department, Hospital Clínico Universitario, Biomedical Research Institute INCLIVA de Valencia, Valencia, Spain;* ⁷*Pediatric Oncology Department, Hospital La Fe, Valencia, Spain;* ⁸*Hospital Niño Jesús, Pediatric Oncology Department, Madrid, Spain;* ⁹*Hospital Niño Jesús, Anatomic Pathology Department, Madrid, Spain;*

¹⁰*Pediatric Oncology Department, Hospital Sant Joan de Déu, Esplugues de Llobregat, Spain;* ¹¹*Department of Pathology, Health Research Institute-Fundación Jiménez Díaz University Hospital. Universidad Autónoma de Madrid, Madrid, Spain;* ¹²*Pathology and Lab Medicine Institute Cleveland Clinic, Cleveland, OH, USA;* ¹³*Pathology, St Jude Children's Research Hospital, Memphis, TN, USA;* ¹⁴*Division of Pathology and Laboratory Medicine, Phoenix Children's Hospital, Phoenix, AZ, USA;* ¹⁵*Pathology, University of Utah/ARUP laboratories, Salt Lake City, UT, USA;* ¹⁶*Pathology, CHU de Rennes, Rennes;* ¹⁷*Department of Pathology, Radboud University Medical Center, Nijmegen, The Netherlands;* ¹⁸*Department of Laboratory Medicine and Pathology at The George Washington University Medical Center, Washington DC, USA;* ¹⁹*National Institutes of Health, National Cancer Institute, Bethesda, MD, USA.*

12:30 – 12:45 PM

PICK-UP BOX LUNCH

12:45 – 1:30 PM

LUNCH SYMPOSIUM-Sponsored by Amgen, Inc.

CASE STUDIES FOCUSED ON PATIENTS WITH CD19-POSITIVE PH- B-ALL IN FRONTLINE CONSOLIDATION

Mitchell S. Cairo, MD

New York Medical College, USA

1:30 – 3:15 PM

PLENARY SESSION III – IMMUNODEFICIENCY ASSOCIATED AND OTHER RARE LYMPHOMAS

Moderators:

Nader El-Mallawany, MD, USA

Wolfram Klapper, MD, Germany

1:30 – 1:50 PM

INBORN ERRORS IN IMMUNITY AND NHL

Shanmuganathan Chandrakasan, MD, USA

1:50 – 2:10 PM

GENETIC AND CLINICAL CHARACTERISTICS OF 54 PEDIATRIC LYMPHOMA PATIENTS WITH VARIANT MUTATION SITES OF UNC13D

Yanlong Duan, MD, China

2:10 – 2:30 PM

EBV DRIVEN PEDIATRIC LYMPHOMAS & LYMPHOPROLIFERATIVE DISORDERS

Nader El-Mallawany, MD, USA

2:30 – 2:45 PM

A Single Cell Atlas of T Cell Lymphoma Reveals Insights into Disease Pathogenesis

Ruoyan Li¹, **Jamie D Matthews**², Emily R. James², Carla Vázquez Amos², Christopher Steel², Shuang Li¹, Olli Duvfa¹, Egor Volchkcov³⁻⁵, Myrisini Tzioni², Chenqu Suo¹, Ekaterina Shelomentseva³⁻⁵, Lorenz Kretschmer³⁻⁵, Dmitry Abramov³⁻⁵, Philip Turton⁶, Ruth F. Jarrett⁷, Michaela Schleder⁸, Lukas Kenner⁸⁻¹¹, G. A. Amos Burke¹², Ming-Qing Du², Sarah Teichmann¹, Suzanne D. Turner^{2,13}

¹Wellcome Sanger Institute, Hinxton, Cambridge, UK CB101SA; ²Department of Pathology, University of Cambridge, Cambridge, UK CB20QQ; ³Faculty of Medicine, Lomonosov Moscow State University, Moscow, Russia; ⁴Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology (D. Rogachev NMRCPHOI) of Ministry of Healthcare of the Russian Federation, 1, Samory Mashela St., Moscow, Russia; ⁵Laboratory of Single Cell Biology, Research Institute of Molecular and Cellular Medicine, RUDN University, Moscow, Russia; ⁶St. James Hospital, The Leeds Teaching Hospitals NHS Trust, Leeds, UK; ⁷MRC-University of Glasgow centre for virus research, Glasgow, Scotland; ⁸Department of Pathology, Medical University of Vienna, 1090, Vienna, Austria; ⁹Unit of Laboratory Animal Pathology, University of Veterinary Medicine Vienna, Vienna, Austria; ¹⁰Center for Biomarker Research in Medicine (CBmed), Graz, Austria; ¹¹Christian Doppler Laboratory for Applied Metabolomics (CDL-AM), Medical University of Vienna, Vienna, Austria; ¹²CRUK Clinical Trials Unit, Birmingham University, Birmingham, UK; Faculty of Medicine, Masaryk University, Brno, Czechia.

2:45 – 3:00 PM

Sequential Post-Transplant Lymphoproliferative Disorders (PTLDs) of Different Histopathology: Comprehensive Clinical and Molecular Characterisation of These Rare Entities

Markéta Racková¹, Andrea Rennerová¹, Markéta Kalinová^{2,3}, Petr Hubáček^{1,4}, Vít Camp⁵, Lucie Winkowska¹, Anna Füreder⁶, Simon Bomken⁷, Dawid Przystupski⁸, Lucie Šrámková¹, Eva Froňková¹, Andishe Attarbaschi⁶

¹Department of Paediatric Haematology and Oncology, Second Faculty of Medicine, Charles University, and University Hospital Motol, Prague, Czech Republic; ²Department of Pathology, 3rd Faculty of Medicine, Charles University Prague and University Hospital Kralovske Vinohrady, Czech Republic; ³Central Laboratories, University Hospital Kralovske Vinohrady, Prague, Czech Republic; ⁴Department of Medical Microbiology, Second Faculty of Medicine, Charles University, and University Hospital Motol, Prague, Czech Republic; ⁵Department of Pathology and Molecular Medicine, Second Faculty of Medicine, Charles University, and University Hospital Motol, Prague, Czech Republic; ⁶Department of Pediatric Hematology and Oncology, St. Anna Children's Hospital, Medical University of Vienna, Vienna, Austria; ⁷Department of Paediatric Haematology and Oncology, Newcastle Upon Tyne Hospitals NHS Foundation Trust, UK; ⁸Department of Paediatric Bone Marrow Transplantation, Haematology and Oncology, Wrocław Medical University, Wrocław, Poland.

3:00 – 3:15 PM

Germline Variants of PIK3CD and PIK3R1 in Pediatric Non-Hodgkin Lymphoma: Insights into The Role of APDS-Associated Alterations

Ida Toelle¹, Marcel te Vrugt¹, Gerrit Randau¹, Katrin Reutter¹, Marc Hotfilder¹, Claudia Sopalla¹, Kenneth Scholten¹, Amelie Alfert¹, Birgit Burkhardt¹

¹Department of Pediatric Hematology and Oncology and NHL-BFM Study Center, University Hospital Muenster, Albert-Schweitzer-Campus 1, Muenster, 48149, Germany.

3:15 – 3:45 PM

COFFEEBREAK

- 3:45 – 5:30 PM** **PLENARY SESSION IV - ADOLESCENT AND YOUNG ADULT LYMPHOMA**
Supported by The Leukemia & Lymphoma Society
Moderators:
Lisa Giulino-Roth, MD, USA
Marta Pillon, MD, ITALY
- 3:45 – 4:05 PM** **TARGETED IMMUNOTHERAPY IN ADOLESCENT AND YOUNG ADULT HODGKIN LYMPHOMA**
Jessica Hochberg, MD, USA
- 4:05 – 4:25 PM** **DISSECTING THE IMMUNE CELL MECHANISMS OF RESISTANCE WITHIN THE CLASSICAL HODGKIN LYMPHOMA TUMOR MICROENVIRONMENT (TME)**
Keynote Lecture #2 - Christian Steidl, MD, Canada
- 4:25 – 4:45 PM** **CHECKPOINT BLOCKADE IN ADOLESCENTS AND YOUNG ADULTS WITH PMBL**
Lisa Giulino-Roth, MD, USA
- 4:45 – 5:00 PM** **Combined Brentuximab Vedotin and Nivolumab for Treatment of Relapsed/Refractory Pediatric Hodgkin lymphoma and Grey Zone Lymphoma**
Grace Kee-See Lam¹, Frankie Wai-Tsoi CHENG¹, Dennis Tak-Loi KU¹, Alan Kwok-Shing Chiang^{1,2}
¹Haematology and Oncology Centre, Department of Pediatrics and Adolescent Medicine, Hong Kong Children's Hospital; ²Department of Pediatrics and Adolescent Medicine, LKS Faculty of Medicine, The University of Hong Kong.
- 5:00 – 5:15 PM** **Cytokine Levels in Pediatric Mediastinal Large B Cell Lymphoma**
Malte Nipper^{1,2}, Will Shephard¹, Christine Damm-Welk^{1,2}, Ilske Oschlies³, Wolfram Klapper³, Birgit Burkhardt⁴, Willi Wößmann^{1,2}, Fabian Knörr^{1,2}
¹Pediatric Hematology and Oncology and NHL-BFM study center, University Medical Center Hamburg-Eppendorf, Hamburg, Germany; ²Research Institute Children's Cancer Center Hamburg, Hamburg, Germany; ³Department of Pathology, Hematopathology Section, University Hospital Schleswig-Holstein, Campus Kiel, Germany; ⁴Pediatric Hematology and Oncology and NHL-BFM study center, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
- 5:15 – 5:30 PM** **Targeted Immunotherapy in Children, Adolescents, and Young Adults (CAYA) with Newly Diagnosed Classical Hodgkin Lymphoma, a single center experience.**
Jessica Hochberg¹, Kayleigh Klose¹, Jaclyn Basso¹, Aliza Gardenswartz¹, Allyson Flower¹, Ana Xavier², Anthony Audino³, Rodney R. Miles⁴; Megan Lim⁵; Stephan D. Voss⁶; Suzanne Braniecki¹, Lauren Harrison¹, and Mitchell S. Cairo^{1,7,8,9}
¹Department of Pediatrics, New York Medical College, Valhalla, NY, USA.; ²Division of Pediatric Hematology-Oncology, University of Alabama, Tuscaloosa, AL, USA; ³Department Pediatrics, Nationwide Children's Hospital, Columbus, OH, USA; ⁴Department of Pathology, University of Utah, Salt Lake City, UT, USA, ⁵Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA, ⁶Department of Radiology, Boston Children's Hospital, Boston, MA, USA; ⁷Department of Medicine, Westchester Medical Center, Valhalla, NY, USA; ⁸Department of Microbiology and Immunology, New York Medical College, Valhalla, NY, USA.; ⁹Department of Cell Biology and Anatomy, New York Medical College, Valhalla, NY, USA.

5:30 – 6:45 PM **WELCOME RECEPTION-POSTER VIEWING**
Poster presenters to be at their posters

SATURDAY, SEPTEMBER 27, 2025

6:30 – 7:45 AM **CONTINENTAL BREAKFAST**

7:00 AM – 5:00 PM **REGISTRATION**

7:00 – 7:45 AM **BREAKFAST SYMPOSIUM -Sponsored by Jazz Pharmaceuticals**
ASPARAGINASE-CONTAINING REGIMENS FOR THE TREATMENT
OF AYA PATIENTS WITH ALL/BLL
John Molina, MD
Cleveland Clinic, USA

7:45 – 8:30 AM **MEET THE PROFESSORS (Choose One Session)**

Session 1 **NEW NHL PATHOLOGICAL ENTITIES**
Wolfram Klapper, MD Germany
Rodney Miles, MD, PhD, USA

Session 2 **MDD AND MRD IN CHILDHOOD AND ADOLESCENT NHL**
Megan Lim, MD, PhD, USA
Christine Damm-Welk, MD, Germany

Session 3 **TARGETED IMMUNOTHERAPY IN MATURE B-NHL**
Matthew Barth, MD, USA
Veronique Minard-Colin, MD, France

Session 4 **CURRENT TECHNOLOGIES TO STUDY GENETIC ALTERATIONS IN NHL**
Itziar Salaverria, MD, Spain

Session 5 **CHILDHOOD AND ADOLESCENT PTLD**
Julia Salmeron-Villalobos, PhD, Spain
Birte Wistinghausen, MD, USA

8:30 – 10:15 AM **PLENARY SESSION V – IMMUNOLOGY, HSCT, AND CELL THERAPY**
Moderators:
Wilhelm Woessmann, MD, Germany
Allyson Flower, MD, USA

8:30 – 8:50 AM **ALLOGENEIC CD7 CAR T CELLS FOR T-ALL/LYMPHOBLASTIC LYMPHOMA**
Shannon Maude, MD, PhD, USA

8:50 – 9:10 AM **CD30 CAR T-CELLS IN CD30+ LYMPHOMA**
Barbara Savoldo, MD, USA

- 9:10 – 9:30 AM **CD19 AND CD20 CAR NK CELLS IN B-CELL LYMPHOMA**
Mitchell S. Cairo, MD, USA
- 9:30 – 9:45 AM **Familial Donor Haploidentical Epstein-Barr Virus (EBV)-specific Cytotoxic T-lymphocytes (CTLs) for Resistant Infections in Children, Adolescents and Young Adults (CAYA) Post Hematopoietic Stem Cell Transplantation (AlloHSCT), and Solid Organ Transplant (SOT)**
Edo Schaefer^{1*}, Allyson Flower^{1*}, Janet Ayello¹, Angeline Jacob¹, Alissa Zhu¹, Yaya Chu¹, Carmella van De Ven¹, Lauren Harrison¹, Erin Morris¹, Yongping Wang⁶, Shalini Shenoy⁷, Dean Lee⁸, Rolla Abu-Arja⁸, Bryon D. Johnson⁹, Tyce Kearn⁹, Michael R. Verneris¹⁰, Julia Chu¹¹, Christopher C. Dvorak¹¹, Kenneth R. Cooke¹², Julie Talano^{9**}, Nancy Bunin^{13**}, Mitchell S. Cairo^{1, 2, 3, 4, 5**}
Department of ¹Pediatrics, ²Medicine, ²Pathology, ⁴Microbiology and Immunology, ⁵Cell Biology and Anatomy, New York Medical College, Valhalla, NY, USA; ⁶Department of Laboratory Medicine, Children’s Hospital of Philadelphia, Philadelphia, PA, USA; ⁷Department of Pediatrics, Washington University, Saint Louis, MO, USA; ⁸Department of Pediatrics, Nationwide Children’s Hospital, Columbus OH, USA; ⁹Department of Pediatrics, Medical College of Wisconsin, Milwaukee, WI, USA; ¹⁰Department of Pediatrics, University of Colorado, Aurora, CO, USA; ¹¹Department of Pediatrics, University of California, San Francisco, San Francisco, CA, USA; ¹²Department of Pediatrics, Johns Hopkins University, Baltimore, MD, USA; ¹³Department of Pediatrics, Children’s Hospital of Philadelphia, Philadelphia, PA, USA.
**Co-Primary authors, **Co-Senior authors.*
- 9:45 – 10:00 AM **Investigating the Role of Maintenance ALK Inhibition after Hematopoietic Cell Transplantation in Patients with ALK-Positive Anaplastic Large Cell Lymphoma**
Michelle Choe^{1,2,3}, Camille Keenan^{2,3}, Julie Rivers^{2,3}, Kasey Leger^{2,3}, Katherine Tarlock^{2,3}, Jennifer Wilkes^{2,3}, Neel Bhatt^{1,2,3}, Ann Dahlberg^{1,2,3}, Corinne Summers^{2,3}, Marie Bleakley^{1,2,3}, Monica Thakar^{1,2,3}
¹Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA, USA; ²Division of Hematology/Oncology, Seattle Children’s Hospital, Seattle, WA, USA; ³Department of Pediatrics, University of Washington, Seattle, WA, USA.
- 10:00 – 10:15 AM **Enhancing CD20.CAR NK Cell Therapy in Rituximab-Resistant Burkitt Lymphoma using IL-15-Based Immunomodulators with NKTR-255 or Anti-CD16-IL15-anti-CD19 TriKE**
Yanling Liao^{1,2}, Meijuan Tian¹, Mishel Ramirez¹, Morgan Anderson-Crannage¹, Shaimaa AbdAllah¹, Edo Schaefer¹, Janet Ayello¹, Mario Marcondes³, Jeffrey S. Miller⁴ and Mitchell Cairo^{1,4,5,6}
¹Department of Pediatrics, ²Department of Medicine, New York Medical College, Valhalla, NY, USA, ³Nektar Therapeutics, San Francisco, CA, USA, ⁴Department of Medicine, University of Minnesota, MN, USA, ⁵Department of Cell Biology & Anatomy, ⁶Department of Pathology, Microbiology & Immunology, New York Medical College, Valhalla, NY, USA.
- 10:15 – 10:45 AM **COFFEE BREAK**
- 10:45 – 12:30 PM **PLENARY SESSION VI –MATURE NK/T-CELL NHL**
Moderators:
Ana Xavier, MD, USA
Yonghong Zhang, MD, PhD, China
- 10:45 – 11:05 AM **NOVEL AND TARGETED APPROACHES TO RELAPSED/REFRACTORY MATURE T-**

CELL LYMPHOMA

Steven Horwitz, MD, USA

- 11:05 –11:25 AM **NOVEL TARGETS IN MATURENK/T-CELL LYMPHOMA**
Ana Xavier, MD, USA
- 11:25 –11:45 AM **CLASSIFICATION AND OUTCOME OF PERIPHERALT-CELL LYMPHOMA NOT OTHERWISE SPECIFIED (NOS): THE JAPANESE EXPERIENCE**
Ritsuro Suzuki, MD, PhD, Japan
- 11:45 –12:00 PM **Secondary HLH in Systemic EBV positive T-cell Lymphoma of Childhood in Adolescent Patients: Case Series**
Carol Lin^{1,2}, Van Huynh^{1,2}, Jamie Frediani^{1,2}, Rishikesh Chavan^{1,2}, Aaron Sassoon¹, Ali Nael^{1,2}, Sonia Morales^{1,2}, Megan Gooch^{1,2}, Jessica Chiu, Natalie Johnson¹, and Lilibeth Torno^{1,2}
¹Children’s Hospital of Orange County, Orange, CA, USA; ²University of California Irvine, Irvine, CA, USA.
- 12:00 –12:15 PM **Peripheral T-Cell Lymphoma in Children and Adolescents**
Kaitlin J. Devine¹, Laura Lenzi¹, Anne F. Reilly¹
¹The Children’s Hospital of Philadelphia, 3401 Civic Center Blvd, Philadelphia PA, USA.
- 12:15 –12:30 PM **Pediatric Non-Hodgkin lymphoma in the Turkish Pediatric Cancer Registry (2009-2024) (TPOG & TPHD data)**
M. Tezer Kutluk¹, Akif Yeşilipek¹
¹Medicana Health Group Zincirlikuyu Hospital, İstanbul, Turkey; Medical Park Hospital, Antalya, Turkey.
- 12:30 – 12:45 PM **PICK-UP BOX LUNCH**
- 12:45 – 1:30 PM** **LUNCH SYMPOSIUM –Sponsored bySobi**
PRIMARY HLH AND GAMIFANT (EMAPALUMAB)
Rikin Shah, MD
Arnold Palmer Hospital for Children at Orlando Health, USA
- 1:30 –3:15 PM** **PLENARY SESSION VII - NOVEL THERAPEUTICS**
Moderators:
Eric Lowe, MD, USA
Carl Allen, MD, USA
- 1:30 –1:50PM **NEXTGENERATION ALK INHIBITORSIN ALCL**
Charlotte Rigaud, MD, France
- 1:50 –2:10PM **DARATUMUMAB TARGETEDTHERAPYIN PEDIATRICT-ALL/LYMPHOBLASTICLYMPHOMA**
Allyson Flower, MD, USA
- 2:10 –2:30PM **CHECKPOINTBLOCKADEINHIBITORS IN CHILDREN, ADOLESCENTS AND YOUNG ADULTS WITH HODGKIN LYMPHOMA ANDALCL**
David Hoogstra, MD, USA
- 2:30 –2:45PM **Glofitamab Plus R-ICE (Rituximab, Ifosfamide, Carboplatin, Etoposide) or as Monotherapy**

in Children and Adolescents with Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma (B-NHL): Analysis From the iMATRIX-GLO Study

Birgit Burkhardt¹, Luciana Vinti², Alba Rubio San Simon³, Hyoung Jin Kang⁴, Stephane Ducassou⁵, Ruta Tuckuviene⁶, Katia Gamel⁷, Jade Wulff⁸, Fabiola Bene Tchaleu⁸, Steven Dmytrasz⁹, Raluca Negricea¹⁰, Beate Wulff⁷, Veronique Minard-Colin¹¹

¹Department Pediatric Hematology, Oncology and BMT, University Hospital Muenster, Muenster, North Rhine-Westphalia, Germany; ²IRCCS Ospedale Pediatrico Bambino Gesù, Rome, Italy; ³Paediatric Haematology-Oncology Department, Children's University Hospital Niño Jesús, Madrid, Spain; ⁴Department of Pediatrics, Seoul National University College of Medicine, Seoul National University Cancer Research Institute, Seoul National University Children's Hospital, Seoul, Gyeonggi Province, South Korea; ⁵Paediatric Haematology-Oncology Department, Centre Hospitalier Universitaire (CHU), Bordeaux, Gironde, France; ⁶Department of Paediatrics and Adolescent Medicine, Rigshospitalet, Copenhagen, Denmark; ⁷Product Development Clinical Oncology and Hematology, F. Hoffmann-La Roche Ltd, Basel, Canton of Basel-Stadt, Switzerland; ⁸Product Development Oncology and Hematology, Genentech, Inc., South San Francisco, CA, USA; ⁹Product Development, Hoffmann-La Roche Ltd, Mississauga, ON, Canada; ¹⁰Roche Products Ltd, Welwyn Garden City, Hertfordshire, UK; ¹¹Department of Pediatric and Adolescent Oncology, INSERM 1015, Gustave Roussy Cancer Campus, Université Paris-Saclay, Villejuif, Ile-de-France, France.

2:45 – 3:00PM

Aiming Towards a Chemotherapy Minimal Regimen for Paediatric Anaplastic Large Cell Lymphoma Using Combination Therapies Involving ALK Inhibitors

Gerardo Enrique Abarca Ríos^{1,2}, Nina Prokoph³, Jamie D. Matthews³, Emily James³, Christopher Steel³, Perla Pucci³, Marta Ferrareso³, Hannah Bilboe³, Valentina Miano³, Callum Malcolm³, Veronika Navrkalová^{1,2}, Šárka Pospíšilová^{1,2}, G. A. Amos Burke^{4,5}, Suzanne D. Turner^{1,3} and **Lucy Hare**^{3,6}

¹Institute of Medical Genetics and Genomics and Department of Internal Medicine, Hematology and Oncology, Faculty of Medicine, Masaryk University and University Hospital Brno, Brno, Czech Republic; ²Central European Institute of Technology, Masaryk University, Brno, Czech Republic ³Division of Cellular and Molecular Pathology, Department of Pathology, University of Cambridge, UK; ⁴Cancer Research UK Clinical Trials Unit, University of Birmingham, Birmingham, UK ⁵Department of Paediatric Oncology and Haematology, Birmingham Children's Hospital, Birmingham, UK; ⁶Department of Paediatric Haematology, Oncology and Palliative Care, Addenbrooke's Hospital, Cambridge, UK.

3:00 – 3:15PM

Utilizing Targeted Immunotherapy to Reduce Oncologic Chemoradiotherapy in CAYA with Advanced MB-NHL

Anthony Audino*¹, Kayleigh Clark*², Aliza Gardenswartz*², Jessica Hochberg², Jaclyn Basso², Ana C. Xavier³, Rodney R. Miles⁴, Stephan D. Voss⁵, Samir Kahwash⁶, Suzanne Branietki², Megan Lim⁷, Lauren Harrison², Stanton Goldman⁸, Mitchell S. Cairo^{2,9,10,11}

¹Department of Pediatrics, Nationwide Children's Hospital, Columbus, OH; ²Department of Pediatrics, New York Medical College, Valhalla, NY; ³Division of Pediatric Hematology-Oncology, University of Alabama at Birmingham, Birmingham, AL; ⁴Department of Pathology, University of Utah, Salt Lake City, UT; ⁵Department of Radiology, Boston Children's Hospital, Boston, MA; ⁶Department of Pathology, Nationwide Children's Hospital, Columbus, OH; ⁷Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY; ⁸Department of Pediatric Hematology-Oncology, Medical City Children's, Dallas, TX; ⁹Department of Medicine, Westchester Medical Center, Valhalla, NY; ¹⁰Department of Microbiology and Immunology, New York Medical College, Valhalla, NY; ¹¹Department of Cell Biology and Anatomy, New York Medical College, Valhalla, NY

*First authors

3:15 –3:40 PM

COFFEEBREAK

3:40 – 6:30 PM

PLENARY SESSION VIII - POSTER DISCUSSION SESSION

Moderators:

Megan Lim, MD, PhD, USA

Michael Link, MD, USA

GROUP 1 MECHANISMS OF RESISTANCE IN CHILDHOOD, ADOLESCENT, YOUNG ADULT NHL

Discussant: Megan Lim, MD, PhD, USA

Circulating Tumor DNA in ALK-Positive Anaplastic Large Cell Lymphoma: A Proof-of-Concept Study

Damien Vasseur^{1,2}, Samuel Abbou³, Ludovic Lacroix^{1,2}, Laurence Lamant⁴, Noémie Pata-Merci², David Sibon⁵, Francesco Facchinetti^{6,7}, Marc Deloger⁸, Floriane Braye⁷, Véronique Minard-Colin³, Laurence Brugières³, Etienne Rouleau¹, Luc Friboulet^{7**}, **Charlotte Rigaud³**

¹Medical Biology and Pathology Department, F-94805, Gustave Roussy, Villejuif, France; ²AMMICA UAR3655/US23, F-94805, Gustave Roussy, Villejuif, France; ³Department of Pediatric and Adolescent Oncology, Gustave Roussy, Villejuif, France; ⁴Department of Pathology, Institut Universitaire du Cancer Toulouse Oncopole, Toulouse, France; ⁵Lymphoid Malignancies Department, Henri Mondor University Hospital, AP-HP, Créteil, France; ⁶Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Boston, MA, USA; ⁷Paris-Saclay University, Gustave Roussy, Inserm U981, Villejuif, France; ⁸Bioinformatics Core Facility, Inserm US23, CNRS UMS 3655, Gustave Roussy, Villejuif, France.

Persistent FDG-PET Uptake after First-Line Therapy in Paediatric Lymphoma and Risk of Progression: A Monocentric Retrospective Analysis

F. Serani¹, **E. Carraro²**, T. Cincotti², D. Cecchin¹, C. Giraud³, A. Biffi², M. Pizzi⁴, L. Mussolin^{2,5}, P. Zucchetta¹, M. Pillon²

¹Nuclear Medicine Unit, Department of Medicine DIMED, University-Hospital of Padova, Padova, Italy; ²Oncohematology Unit, Department of Woman and Child Health, University-Hospital of Padova, Padova, Italy; ³Unit of Advanced Clinical and Translational Imaging, Department of Cardiac, Thoracic, Vascular Sciences and Public Health-DCTV, University of Padova, Padova, Italy; ⁴General Pathology and Cytopathology Unit, Department of Medicine-DMED, University-Hospital of Padova, Padova, Italy; ⁵Pediatric Research Institute Foundation "Città della Speranza", Padua, Italy.

Whole Exome Sequencing in Pediatric ALCL: High Tumor Mutational Burden Characterizes Early Relapse Patients

Matteo Marzi^{1,2}, Alessia Danieli^{1,2}, Daniele Ramazzotti³, Carlo Zanon^{1,2}, Matteo Villa³, Federica Malighetti³, Carlotta Caterina Damanti^{1,2}, Gaia Martire^{1,2}, Elisa Carraro¹, Andrea Carraro⁴, Marco Pizzi⁴, Teresa Battaglia⁵, Rosa Maria Mura⁶, Annalisa Tondo⁷, Elisabetta Schiavello⁸, Marta PilloN¹, Luca Mologni³, Lara Mussolin^{1,2}

¹Maternal and Child Health Department, University of Padova, Padova, Italy; ²Istituto di Ricerca Pediatrica Città della Speranza, Padova, Italy; ³Department of Medicine and Surgery, University of Milano-Bicocca, Monza, Italy; ⁴General Pathology and Cytopathology Unit, Department of Medicine-DMED, University-Hospital of Padova, Padova, Italy; ⁵Clinical Oncology Unit, IRCCS Istituto Giannina Gaslini, 16147 Genoa, Italy; ⁶Pediatric Oncology Unit, Azienda Ospedaliera Brotzu, Cagliari, Italy; ⁷Department of Pediatric Hematology Oncology, Meyer Children's Hospital IRCCS, Florence, Italy; ⁸Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.

Investigating Kinase Dependencies in ALK⁺ALCL

Jacques Cornwell^{1*}, Christopher Steel^{1*}, Dawid Przystupski², Rogier ten Hoopen¹, Jamie D. Matthews¹,

Lucy Hare^{1,3}, Nina Prokoph¹, G. A. Amos Burke¹, Suzanne D. Turner^{1,5}

*Authors contributed equally

¹Department of Pathology, University of Cambridge, Cambridge, UK; ²Department of Paediatric Bone Marrow Transplantation, Oncology and Haematology, Wroclaw Medical University, Poland; ³Department of Paediatric Haematology, Oncology and Palliative Care, Addenbrooke's Hospital, Cambridge, UK; ⁴CRUK Clinical Trials Unit, University of Birmingham, UK; ⁵Faculty of Medicine, Masaryk University, Brno, Czechia.

Construction and Characterization of a Single-Center Childhood non-Hodgkin Lymphoma PDX Model Library

Ziping Xing¹, Zifeng Li, Hongsheng Wang¹, Maoxiang Qian¹, **Xiaowen Zhai**¹

¹Department of Hematology and Oncology, Children's Hospital of Fudan University, National Children's Medical Center, Shanghai, China.

GROUP 2 RARE CHILDHOOD, ADOLESCENT, YOUNG ADULT NHL

Discussant: Michael Link, MD, USA

Extramedullary Plasmacytoma in Children is a Genetically Distinct Localized Neoplasia Curable by Surgical Resection

Ilske Oschlies^{1*}, Julia Richter^{1*}, Amelie Alfert^{2*}, Fernando Chahud³, Stephanie Mueller², Ingrid Simonitsch-Klupp⁴, Hannah von Mersi⁵, Andishe Attarbaschi⁵⁻⁶, Karoline Koch¹, Christoph Schaefer⁷, Monika Brüggemann⁸, Cecilia Bozzetti⁸, Wilhelm Woessmann⁹, Birgit Burkhardt², and **Wolfram Klapper**¹

¹Department of Pathology, Hematopathology Section, University Hospital Schleswig-Holstein, Campus Kiel, Germany; ²Department of Paediatric Hematology and Oncology and NHL-BFM study center, University Hospital Muenster, Muenster, Germany; ³Department of Pathology, Ribeirão Preto Medical School, University of São Paulo, Brazil; ⁴Department of Pathology, Medical University of Vienna, Austria; ⁵Department of Pediatric Hematology and Oncology, St. Anna Children's Hospital, Medical University of Vienna, Vienna, Austria; ⁶St. Anna Children's Cancer Research Institute, Vienna, Austria; ⁷Department of Oncology, Hematology and Stem Cell Transplantation with Division of Pneumology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany; ⁸Department of Haematology and Oncology, University Hospital Schleswig-Holstein, Campus Kiel, Germany; ⁹Pediatric Hematology and Oncology and NHL-BFM study center, University Medical Center Hamburg-Eppendorf, Hamburg, Germany;

* These authors contributed equally.

CLINICAL OUTCOMELINICAL OUTCOME PREDICTION IN PEDIATRIC PRIMARY MEDIASTINAL B CELL LYMPHOMA – A JOINT BFM AND INTER-B-NHL RITUX 2010 ANALYSIS

Fabian Knörr^{1*}, Sarah Flora Jonas^{2*}, Amos Burke³, Sarah Alexander⁴, Mara Andres⁵, Andishe Atterbaschi⁶, Anne Auperin², Birgit Burkhardt⁷, Francesco Ceppi⁸, Edita Kabickova⁹, Peggy Dartigues¹⁰, Wolfram Klapper¹¹, Mary Taj¹², Martin Zimmermann¹³, Veronique Minard-Colin^{14,15*}, Willi Woessmann^{1*}, Friederike Meyer-Wentrup^{16*}

¹Pediatric Hematology and Oncology and NHL-BFM Study Center, University Medical Center Hamburg-Eppendorf, Hamburg, Germany; ²Biostatistics and Epidemiology Office, Gustave Roussy, INSERM U1018 Oncostat, Labelled Ligue Contre le Cancer, Université Paris-Saclay, Villejuif, France; ³Cancer Research UK Clinical Trials Unit (CRCTU), University of Birmingham, College of Medicine and Health, Birmingham, UK; ⁴Division of Pediatric Haematology/Oncology, Hospital for Sick Children, University of Toronto, Toronto, ON, Canada; ⁵Department of Pediatric Hematology and Oncology, University Hospital La Fe, Valencia, Spain; ⁶Department of Pediatric Hematology and Oncology, St. Anna Children's Hospital, Medical University of Vienna, Vienna, Austria; ⁷Department of Paediatric Hematology and Oncology and NHL-BFM Study Center, University Hospital Münster, Münster, Germany; ⁸Division of Pediatrics, Department of Woman-Mother-Child, Pediatric Hematology-Oncology Unit, University Hospital of Lausanne and University of Lausanne, Lausanne, Switzerland; ⁹Department of Pediatric Hematology and Oncology,

Charles University and University Hospital Motol, Prague, Czech Republic; ¹⁰Department of Pathology, Gustave Roussy, Université Paris-Saclay, Villejuif, France; ¹¹Department of Pathology, Hematopathology Section, University Hospital Schleswig-Holstein, Campus Kiel, Germany; ¹²Department of Pediatrics, The Royal Marsden NHS Foundation Trust, London, UK; ¹³Department of Pediatric Hematology and Oncology, Hannover Medical School, Hannover, Germany; ¹⁴Departments of Pediatric and Adolescent Oncology, Gustave Roussy, Université Paris-Saclay, Villejuif, France; ¹⁵INSERM U1015, Gustave Roussy, Université Paris-Saclay, Villejuif, France; ¹⁶Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands.
** These authors contributed equally to this work*

Impact of Time of Onset on Pediatric Post-Transplant Lymphoproliferative Disorder Outcomes: Results from a Prospective/Retrospective Multicenter Study

Lianna J. Marks¹, Michael Green², Mansi Agarwal³, Charles W. Goss³, Vikas R. Dharnidharka⁴ for the PTLD-MSMS group.

¹Stanford University School of Medicine, Palo Alto, CA, USA; ²University of Pittsburgh School of Medicine, Pediatrics, Pittsburgh, PA, USA; ³Washington University School of Medicine in St. Louis, Biostatistics, St. Louis, MO, USA; ⁴Robert Wood Johnson Medical School at Rutgers University, Pediatrics, New Brunswick, NJ, USA.

Systemic Epstein-Barr virus-positive T-cell Lymphoma of Childhood: A Case Series and Review of the Literature

Maiah Zarrabi¹, Christine Cahaney², Lindsay F. Schwartz², Carol Lin³, Alexandra E. Kovach⁴, Jamie Stokke¹
¹Children's Hospital Los Angeles, Cancer and Blood Disease Institute; University of Southern California, Los Angeles, CA, USA; ²University of Chicago Comer Children's Hospital, Chicago, IL, USA; ³Children's Hospital of Orange County; University of California Irvine, Orange, CA, USA; ⁴Children's Hospital of Los Angeles, Department of Pathology and Laboratory Medicine; University of Southern California, Los Angeles, CA, USA.

GROUP 3 HSCT, CELL THERAPY AND TARGETED THERAPY

Discussant: Wilhelm Woessmann, MD, Germany

Chemotherapy-Only Treatment in Low and Standard Risk Mature B-Cell Non-Hodgkin Lymphoma in Children and Adolescents: Pooled Analysis of the FAB/LMB96 AND LMB2001 Studies

Minard-Colin V*, Aupérin A*, Burke GAA, Taj M, Meyer - Wentrup F, de Ville de Goyet M, Smith O, Haouy S, Ducassou S, Bollard CM, Leruste A, Molina T, Miles RR, Gross TG, Alexander S, Patte C**, Cairo MS**

*Share first authorship **Share last authorship

¹Unit of Biostatistics and Epidemiology, Gustave Roussy, Université Paris-Saclay, Villejuif, France; ²Cancer Research UK Clinical Trials Unit (CRCTU), Institute of Cancer and Genomic Sciences, University of Birmingham, Edgbaston, Birmingham, United Kingdom; ³Department of Paediatric Oncology, Royal Marsden Hospital, Sutton, Surrey, UK; ⁴Princess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands; ⁵Cliniques universitaires Saint-Luc and Institut de Recherche Expérimentale et Clinique UCLouvain, Bruxelles, Belgium; ⁶National Children's Cancer Service, Children's Health Ireland at Crumlin, Dublin, Ireland; ⁷Department of Pediatric and Adolescent Haematology and Oncology, CHU Montpellier, Montpellier, France; ⁸Department of Pediatric and Adolescent Haematology and Oncology; CHU Pellegrin, Bordeaux, France; ⁹Center for Cancer and Immunology Research, Children's National Hospital, Washington, D.C. USA; ¹⁰Department of Pediatric and Adolescent Oncology, Institut Curie, Paris, France; ¹¹Pathology Department, Necker and Robert Debré Hospitals, Paris, France; ¹²University of Utah, Department of Pathology, Salt Lake City, UT, USA; ¹³Center for Cancer and Blood Disorders, Children's Hospital of Colorado, Aurora, USA; ¹⁴Hospital for Sick Children, University of Toronto, Toronto, Canada; ¹⁵Cairo MS: Department of Pediatrics, New York Medical College, Valhalla, NY, USA.

A Phase 1 Trial of Targeted Immunotherapy with Daratumumab Following Myeloablative Total Body Irradiation (TBI)-Based Conditioning and Allogeneic Hematopoietic Cell Transplantation (HCT) in Children, Adolescents and Young Adults with High-Risk T-Cell Acute Lymphoblastic Leukemia and Lymphoma (T-ALL/T-LLy) (ALLO-T-DART): A PTCTC Facilitated Study

Troy C. Quigg^{1*}, **Allyson Flower^{2*}**, David T. Teachey³, Megan Lim⁴, Yanling Liao², Lauren Harrison², Erin Morris², Stephan Voss⁵, Rodney Miles⁶, Xiaokui Mo⁷, Adam Olshen⁸, Alix E. Seif³, and Mitchell S. Cairo²
¹*Pediatric Blood and Marrow Transplantation, Helen DeVos Children's Hospital, Michigan State University College of Human Medicine;* ²*Pediatric Hematology/Oncology/Stem Cell Transplantation, New York Medical College;* ³*Children's Hospital of Philadelphia, University of Pennsylvania School of Medicine;* ⁴*Department of Pathology, Memorial Sloan Kettering Cancer Center;* ⁵*Boston Children's Hospital;* ⁶*University of Utah Health Sciences Center;* ⁷*Ohio State University;* ⁸*University of California, San Francisco*
**Primary co-authors*

Combinatorial Natural Killer (NK) Cell-Based Immunotherapy to circumvent resistance in Rituximab-Resistant Burkitt Lymphoma (BL)

Meijuan Tian¹, Yanling Liao^{1,2}, Shaimaa AbdAllah¹, Mishel Ramirez¹, Janet Ayello¹, Morgan Anderson-Crannage¹, Edo Schaefer¹, Mario Marcondes³, Mitchell Cairo^{1,2,4,5}
¹*Department of Pediatrics,* ²*Department of Medicine, New York Medical College, Valhalla, NY, USA;* ³*Nektar Therapeutics, San Francisco, CA, USA;* ⁴*Department of Cell Biology & Anatomy,* ⁵*Department of Pathology, Microbiology & Immunology, New York Medical College, Valhalla, NY, USA.*

Rasburicase vs. Allopurinol: Mortality in Hematological Malignancies Post Anti hyperuricemic Therapy - Real-World Study

Samuel G. Hilbert¹, Jack Ray Gallagher², Yvonne Barnes³, Edward Drea³, Christopher Clark³, Susan Carroll², Mitchell Stuart Cairo¹
¹*Maria Fareri Children's Hospital Westchester Medical Center (WMC), New York Medical College, Valhalla, NY, USA;* ²*Clarity Pharma Research LLC, Spartanburg, SC, USA;* ³*Sanofi, Cambridge, MA, USA.*

Pilot Study Using Induction Chemo-Immunotherapy Followed by Consolidation with Reduced Toxicity Conditioning and Allogeneic Stem Cell Transplant In Advanced Stage Mature Non-Anaplastic T- or NK-cell Lymphoma/Leukemia in Children, Adolescent, and Young Adults (CAYA)

Ana C. Xavier^{1*}, Allyson Flower², Lauren Harrison², Rodney R. Miles³, Stephan D. Voss⁴, Megan Lim⁵, Mitchell S. Cairo^{2,6,7,8,9}
¹*Division of Hematology/Oncology, Department of Pediatrics, University of Alabama at Birmingham, Alabama, USA;* ²*Department of Pediatrics, New York Medical College, Valhalla, NY, USA;* ³*Department of Pathology, University of Utah, Salt Lake City, UT, USA;* ⁴*Division of Oncologic Imaging, Department of Radiology, Boston Children's Hospital, Harvard Medical School, Boston, MA, USA;* ⁵*Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York City, NY, USA;* ⁶*Department of Microbiology & Immunology, New York Medical College, Valhalla, NY, USA;* ⁷*Department of Medicine, New York Medical College, Valhalla, NY, USA;* ⁸*Department of Pathology, New York Medical College, Valhalla, NY, USA;* ⁹*Department of Cell Biology & Anatomy, New York Medical College, Valhalla, NY, USA.*

GROUP 4 GLOBAL CHILDHOOD, ADOLESCENT, YOUNG ADULT NHL

Discussant: Ritsuro Suzuki, MD, PhD, Japan

CLINICAL OUTCOME OF PEDIATRIC EPSTEIN-BARR VIRUS-ASSOCIATED T- AND NK-CELL LYMPHOPROLIFERATIVE DISEASE

Evelyn R Lu^{1,2}, Mark MH Cheng³, Eric CH Fu², Grace KS Lam², **Alan KS Chiang**^{1,2}

¹Department of Pediatrics and Adolescent Medicine, LKS Faculty of Medicine, The University of Hong Kong, Hong Kong SAR, China; ²Department of Pediatrics and Adolescent Medicine, Hong Kong Children's Hospital, Hong Kong SAR, China; ³Department of Pediatrics and Adolescent Medicine, Princess Margaret Hospital, Hong Kong SAR, China.

Improving Global Treatment Outcomes of Children Diagnosed with Burkitt Lymphoma

Adiba Khan¹, Marta Ferraresso¹, Sylvestor Kadhumbula², Godwin Winston², Stephanie Wenlock¹, Nixon Nyonzima², Fadhil Geriga², Joyce Balagadde-Kambugu², Jackson Orem^{2*}, Suzanne D. Turner^{1,2}

¹Department of Pathology, University of Cambridge, Cambridge, United Kingdom; ²Uganda Cancer Institute, Kampala, Uganda.

Survival Outcomes in Adolescent Hodgkin and Non-Hodgkin Lymphomas: A Retrospective Study at a Tertiary care centre in North Eastern India

Chandra Mohan Kumar¹, Tulasiram Nalam¹, Arnab Ghorui¹, Gurleen Kaur Kalra¹

¹All India Institute of Medical Sciences Patna, Bihar, India. PIN 801507.

Advances in Pediatric Lymphoblastic Lymphoma: Demographic, Clinical Characteristics, Treatment and Long-Term Outcome: Institutional Experience over 30 years

Rejin Kebudi^{1*}, Ulku Miray Yıldırım¹, Başak Koç Şenol¹, Bülent Zülfikar¹

¹Istanbul University, Oncology Institute, Pediatric Hematology-Oncology, Istanbul, Türkiye

Poorer Survival in Pediatric Post-Transplant Lymphoproliferative Disorder (PTLD) Diagnosed during Adolescence

Mona Yuan¹, ZheZhen Jin¹, Sonika Reddy¹, Kathryn Henschel¹, Megan Ford¹, Mercedes Martinez¹, Marc Richmond¹, Lorena Reis¹, Prakash Satwani, Manuela Orjuela-Grimm¹

¹Columbia University Medical Center, New York, NY, USA

6:30 PM TAKE POSTERS DOWN
7:00 – 10:00 PM FACULTY/STAFF DINNER (Invitee only)

SUNDAY, SEPTEMBER 28, 2025

6:30 – 7:45 AM CONTINENTAL BREAKFAST
7:00 – 8:30 AM REGISTRATION
7:00 – 7:45 AM BREAKFAST SYMPOSIUM – Sponsored by Servier Pharmaceuticals
THE ALL-IN APPROACH: CONFRONTING ALL WITH A MULTI-AGENT CHEMOTHERAPY REGIMEN
Natalie S. Bezler, MD
Center for Cancer & Blood Disorders at Connecticut Children's Medical Center, USA
7:45 – 8:30 AM MEET THE PROFESSORS (CHOOSE ONE SESSION)
Session 1 **DIAGNOSIS AND MANAGEMENT OF ALK+ ALCL**
Wilhelm Woessmann, MD, Germany
Amos Burke, MD, UK

- Session 2 **MANAGEMENT OF SECONDARY HLLH SECONDARY TO MALIGNANT NHL**
Steven Horwitz, MD, USA
- Session 3 **MOLECULAR BASED THERAPEUTIC APPROACHES TO LANGERHANS HISTIOCYTOSIS**
Carl Allen, MD, PhD, USA
- Session 4 **LATE EFFECTS IN CHILDHOOD NHL**
Matthew Ehrhardt, MD, USA
- Session 5 **DIAGNOSIS AND MANAGEMENT OF T-LYMPHOBLASTIC LYMPHOMA/ALL**
David Teachey, MD, USA
Robert Hayashi, MD, USA

8:30 – 10:00 AM PLENARY SESSION IX - BEST ORAL ABSTRACTS
Moderator:
Mitchell S. Cairo, MD, USA

8:30 – 8:45 AM **Qualitative and quantitative minimal disease measurement in ALK-positive anaplastic large cell lymphoma: efficacy of international quality control and event-free survival according to different minimal disseminated disease cut-offs**

Christine Damm-Welk¹, Cathy Quelen², Laurence Lamant², Gaia Martire^{3,4}, Lukas Duscher¹, Reiji Fukano⁵, Yuka Iijima-Yamashita⁶, Itziar Salleva⁷, Julia Salmeron-Villalobos⁷, Liz Yuet-Ping Yuen⁸, Yu-Kwan Tong⁸, Suzanne D. Turner⁹, Rogier ten Hoopen⁹, Edwin Sonneveld¹⁰, Eric Strengman¹⁰, Maria Hansen¹¹, Guy Wayne Novotny¹¹, Megan S. Lim¹², Rui Wu¹², Ariel Long¹³, Feng Xu¹³, Marilyn M. Li¹³, Grace Kee-See Lam¹⁴, Jaime Verdu-Amoros¹⁵, Charlotte Rigaud¹⁶, Martin Zimmermann¹⁷, Marta Pillon², Wilhelm Woessmann¹, Lara Mussolin^{3,4}

¹*Pediatric Hematology and Oncology and NHL-BFM study center, University Medical Center Hamburg-Eppendorf, Hamburg, Germany;* ²*Pathology Department, CHU de Toulouse, Toulouse University, Toulouse, France;* ³*Maternal and Child Health Department, Padova University, 35128 Padova, Italy;* ⁴*Istituto di Ricerca Pediatrica Città della Speranza, 35127 Padova, Italy;* ⁵*Department of Pediatrics, School of Medicine, University of Occupational and Environmental Health, Kitakyushu 807-8555, Japan;* ⁶*Department of Advanced Diagnosis, NHO Nagoya Medical Center Clinical Research Center, Nagoya, Japan;* ⁷*Fundació De Recerca Clínic Barcelona-Institut D'investigacions Biomèdiques August Pi I Sunyer (FRCB-IDIBAPS), Barcelona, Spain;* ⁸*Department of Pathology, Hong Kong Children's Hospital, Hong Kong SAR, China;* ⁹*Division of Cellular and Molecular Pathology, Department of Pathology, University of Cambridge, Cambridge, UK;* ¹⁰*Princess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands;* ¹¹*Department of Clinical Genetics Rigshospitalet, Copenhagen University Hospital Copenhagen Denmark;* ¹²*Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA;* ¹³*Department of Pathology and Laboratory Medicine, Children's Hospital of Philadelphia, Philadelphia, PA, USA;* ¹⁴*Haematology and Oncology Centre, Department of Paediatrics and Adolescent Medicine, Hong Kong Children's Hospital, Hong Kong, China;* ¹⁵*Hospital Clínico Universitario, Pediatric Oncology and Hematology Department, Biomedical Research Institute INCLIVA de Valencia, Valencia, Spain;* ¹⁶*Department of Children and Adolescents Oncology, Gustave-Roussy Cancer, Paris-Saclay University, Villejuif, France;* ¹⁷*Department of Pediatric Hematology and Oncology, Hannover Medical School, and NHL-BFM Study Center, Hannover, Germany.*

8:45 – 9:00 AM

Mutation Sites Influence Prognostic Significance of TP53 Mutations in Pediatric B-Cell Non-

Hodgkin Lymphoma

Marcel te Vrugt¹, Amelie Alfert¹, Lara Mussolin², Mara Andres³, Alex Blain⁴, Chris Bacon⁴, Elisa Carraro², Christine Damm-Welk⁵, Eric Hermann⁶, Marc Hotfilder¹, Fabian Knörr⁵, Luisa Kruppa⁵, Claudia Lanvers-Kaminsky¹, Sara Mato⁷, Gaia Martire², Stephanie Mueller¹, Alexander Newman⁴, Katrin Reutter¹, Elina Richter¹, Gerrit Randau¹, Vikki Rand⁸, Kenneth Scholten¹, Ida Tölle¹, Jaime Verdu-Amoros^{7,9}, Simon Bomken⁴, Itziar Salaverria^{7,10}, Martin Zimmermann¹¹, Birgit Burkhardt¹

¹Department of Pediatric Hematology and Oncology and NHL-BFM Study Center, University Hospital Muenster, Muenster, Germany; ²Hematology, Oncology and Stem Cell Transplant Division, Maternal and Child Health Department, University of Padova and University Hospital, Padova, Italy; ³Paediatric Hematology and Oncology Department, Hospital Universitario y Politécnico La Fe de Valencia, Valencia, Spain; ⁴Wolfson Childhood Cancer Research Centre, Translational and Clinical Research Institute, Newcastle University, UK; ⁵Department of Pediatric Hematology and Oncology and NHL-BFM Study Center, University Medical Center Hamburg-Eppendorf, Hamburg, Germany; ⁶Department of Molecular and Cell Biology, University of California, Berkeley, CA, USA; ⁷Paediatric Hematology and Oncology Department, Clinic University Hospital of Valencia, INCLIVA Biomedical Research Institute, Valencia, Spain; ⁸School of Health & Life Sciences and National Horizons Centre, Teesside University, UK; ⁹Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain; ¹⁰Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain; ¹¹Department of Pediatric Hematology and Oncology, Hannover Medical School, Hannover, Germany.

9:00 – 9:15AM

Genomic Alterations of B-Cell Non-Hodgkin Lymphoma in Pediatric Patients with Inborn Errors of Immunity

Sara Mato^{1,2}, Leonie Frauenfeld^{1,2}, Julia Richter³, Ariadna Colmenero^{1,2}, Julia Salmeron-Villalobos¹, Angela Deya-Martinez⁴, Natalia Castrejón de Anta^{2,5}, Eugenia Garcia-Fernandez⁶, Konnie Hebeda⁷, Ingrid Simonitsch-Klupp⁸, Jaime Verdú-Amorós^{9,10}, Mara Andrés¹¹, Birgit Burkhardt¹², Kenneth Scholten¹², Noelia García¹, María José Ortega¹³, Pilar Guerra-Garcia¹⁴, Berta González¹⁴, Margarita Llavador¹⁵, Luis Ignacio González¹⁶, Eduardo Quiroga¹⁷, Itziar Astigarraga^{18,19}, Idoia Martin-Guerrero^{18,20}, Elias Campo^{1,2,5}, Wolfram Klapper³, Olga Balagué⁵, Itziar Salaverria¹

¹Institut d'Investigacions Biomèdiques August Pi i Sunyer, Barcelona, Spain; ²Universitat de Barcelona, Barcelona, Spain; ³Pathology Department, UKSH Kiel, Germany; ⁴Clinical Immunology and Primary Immunodeficiencies Unit, Hospital Sant Joan de Déu, Barcelona, Spain; ⁵Pathology Department, Hospital Clinic de Barcelona, Spain; ⁶Pathology Department, Hospital Universitario La Paz, Spain; ⁷Pathology, Radboud UMC, Nijmegen, The Netherlands; ⁸Pathology Department, AKH Wien, Austria; ⁹Pediatric Oncology, Hospital Clínico de Valencia, Spain. Biomedical Research Institute, INCLIVA; ¹⁰Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain; ¹¹Pediatric Oncology, Hospital La Fe, Valencia, Spain; ¹²Department of Pediatric Hematology and Oncology and NHL-BFM Study Center, University Hospital Muenster, Muenster, Germany; ¹³Pediatric Oncology, Hospital Virgen de las Nieves, Granada, Spain; ¹⁴Pediatric Oncology, Hospital Universitario La Paz, Spain; ¹⁵Pathology Department, Hospital La Fe, Valencia, Spain; ¹⁶Immunodeficiencies Unit. Hospital 12 de Octubre, Madrid, Spain; ¹⁷Pediatric Oncology, Hospital Virgen del Rocío, Sevilla, Spain; ¹⁸Pediatric Oncology Group, BioBizkaia Health Research Institute, Barakaldo, Spain; ¹⁹Pediatrics Department, Hospital Universitario Cruces, UPV/EHU. Barakaldo, Spain; ²⁰Department of Genetics, Physical Anthropology & Animal Physiology, Science and Technology Faculty, University of the Basque Country (UPV/EHU), Leioa, Spain.

- 9:15 –9:30AM **Clinical, Histological, and Genetic Characterization of Aggressive B-Cell Lymphoproliferations in Patients with Inborn Errors of Immunity**
Antoine Gondé¹, **Julie Bruneau**², Lucile Couronné³, Morgane Cheminant⁴, Vahid Asnafi³, Thierry J. Molina², Alain Fischer¹, Felipe Suarez⁴, Bénédicte Neven¹
¹Pediatric Immunology, Hematology and Rheumatology Department, Hôpital Necker-Enfants Malades, Assistance Publique-Hôpitaux de Paris, Paris, France; ²Pathology Department, Hôpital Necker-Enfants Malades, Assistance Publique-Hôpitaux de Paris, Paris, France; ³Laboratory of Onco-Hematology, Hôpital Necker-Enfants Malades, Assistance Publique-Hôpitaux de Paris, Paris, France; ⁴Adult Hematology, Hôpital Necker-Enfants Malades, Assistance Publique-Hôpitaux de Paris, Paris, France.
- 9:30 –9:45AM **Metabolic-Only Response Assessment Allows for Omission of Residual Node Radiation Therapy (RNRT) for the Majority of Patients with Classical Hodgkin Lymphoma (cHL) while Maintaining Excellent Event Free (EFS) and Overall Survival (OS): A Report from the Pediatric Hodgkin Consortium’s Phase 2 Study cHOD17 (NCT03755804)**
Jamie E. Flerlage¹, Angela M. Feraco², Yiwang Zhou³, Ying Zheng³, John T. Lucas Jr³, Stephanie B. Dixon³, Jessi Rogers Blake³, Lindsay Wilemon³, Bryan A. Roberts³, Lianna J. Marks⁴, Alison M. Friedmann⁵, Shannon MacDonald⁵, Howard J. Weinstein⁵, Pedro de Alarcon⁶, Eric C. Larsen⁷, Torunn I. Yock⁵, Susan Hiniker⁴, Christine Bolen⁸, Stephan D. Voss⁹, Michael P. Link⁴, **Matthew J. Ehrhardt**³, and the Pediatric Hodgkin Consortium
¹University of Rochester, Rochester, NY, USA; ²Dana-Farber Cancer Institute, Boston, MA, USA; ³St. Jude Children’s Research Hospital, Memphis, TN, USA; ⁴Stanford University School of Medicine, Stanford, CA, USA; ⁵Massachusetts General Hospital, Boston, MA, USA; ⁶University of Illinois College of Medicine Peoria, Peoria, IL, USA; ⁷Maine Children’s Cancer Program, Scarborough, ME, USA; ⁸Novant Health Hemby Children’s Hospital, Charlotte, NC, USA; ⁹Boston Children’s Hospital, Boston, MA, USA.
- 9:45 –10:00AM **Prognosis of Childhood, Adolescent and Young Adult ENKL Patients after Hematopoietic Stem Cell Transplantation**
Ayumi Fujimoto¹, Tatsuhiko Anzai², Koji Kato³, Junji Suzumiya⁴, Noboru Asada⁵, Mizuki Watanabe⁶, Hideyuki Nakazawa⁷, Koichi Onodera⁸, Nobuhiro Hiramoto⁹, Junya Kanda¹⁰, Takahiro Fukuda⁶, Yoshiko Atsuta¹¹, Yuhki Koga¹², Shinichi Kako¹³, Ritsuro Suzuki¹
¹Division of Hematology and Oncology, Department of Internal Medicine, Faculty of Medicine, Shimane University, Izumo, Japan; ²Department of Biostatistics, Institute of Science Tokyo, Tokyo, Japan; ³Department of Medicine and Biosystemic Sciences, Kyushu University Graduate School of Medicine, Fukuoka, Japan; ⁴Department of Hematology, Koga Community Hospital, Yaizu, Japan; ⁵Department of Hematology and Oncology, Okayama University Hospital, Okayama, Japan; ⁶Department of Hematopoietic Stem Cell Transplantation, National Cancer Center Hospital, Tokyo, Japan; ⁷Department of Hematology, Shinshu University School of Medicine, Matsumoto, Japan; ⁸Department of Hematology, Tohoku University Hospital, Sendai, Japan; ⁹Department of Hematology, Kobe City Medical Center General Hospital, Kobe, Japan; ¹⁰Department of Hematology, Graduate School of Medicine, Kyoto University, Kyoto, Japan; ¹¹Japanese Data Center for Hematopoietic Cell Transplantation; ¹²Department of Pediatrics, National Hospital Organization Kyushu Cancer Center, Fukuoka, Japan; ¹³Division of Hematology, Jichi Medical University Saitama Medical Center, Saitama, Japan.
- 10:00 –10:15AM **COFFEEBREAK**

- 10:15 –12:15 PM** **PLENARY SESSION X - LYMPHOBLASTIC LYMPHOMA & ANAPLASTIC LARGE CELL LYMPHOMA**
Moderators:
 Birgit Burkhardt, MD, PhD, Germany
 Suzanne Turner, PhD, UK
- 10:15 –10:35 AM** **CNS-THERAPY AND PROPHYLAXIS IN T-CELL LYMPHOMA IN CHILDREN AND ADOLESCENTS**
 Wilhelm Woessmann, MD, Germany
- 10:35 –10:55 AM** **DIFFERENT *NOTCH1* FUSIONS IDENTIFIED BY RNAseq CONSTITUTE A HR GROUP IN T-LBL EASILY IDENTIFIABLE WITH CCL17 AS BIOMARKER**
 Jan Loeffen, MD, PhD, Netherlands
- 10:55 –11:15 AM** **TARGETING CCR7-P13Kγ TO REDUCE RESISTANCE TO TKI THERAPY IN ALK+ ALCL**
 Roberto Chiarle, MD, Italy
- 11:15 –11:30 AM** ***NPM*: ALK Transcript Levels and Anti-ALK Autoantibody Titers as Biomarkers for Outcome in Pediatric ALK+ Anaplastic Large Cell Lymphoma Treated with Brentuximab Vedotin or Crizotinib in Combination with Chemotherapy: COG ANHL12P1**
Christopher J. Forlenza¹, David J. Hoogstra², Lauren Saguilig³, Donald A. Barkauskas³, Suzanne D. Turner PhD⁴, Nina Prokoph PhD⁴, Perla Pucci PhD⁴, Lucy Hare MD PhD⁴, Leila Jahangiri PhD⁴, Rui Wu¹, Kojo S. Elenitoba-Johnson¹, Eric J. Lowe⁵, Megan S. Lim¹
¹Memorial Sloan Kettering Cancer Center, New York, NY, USA; ²Helen Devos Children's Hospital At Spectrum Health, Grand Rapids, MI, USA; ³Children's Oncology Group Operations Statistics and Data Center, Monrovia, CA, USA; ⁴University of Cambridge, Cambridge, UK; ⁵Children's Hospital of the King's Daughters, Norfolk, VA, USA.
- 11:30 –11:45 AM** **Recurrent Molecular Variants, Clonal Evolution and Clinical Relevance in Pediatric and Adult T-Cell Lymphoblastic Neoplasia**
Marcel te Vrugt¹, Sarah Sandmann², Gerrit Randau¹, Thomas Beder³, Martin Neumann⁴, Pia Lange², Amelie Alfert¹, Stephanie Mueller¹, Marc Hotfilder¹, Corinne Rossi⁵, Cornelia Eckert⁶, Anja Moericke⁷, Johanna Maria Horns⁴, Martin Zimmermann⁸, Julian Varghese⁹, Monika Brüggemann⁴, Birgit Burkhardt¹
¹Pediatric Hematology and Oncology and NHL-BFM study center, University Hospital Muenster, Muenster, 48149, Germany; ²Institute of Medical Informatics, University of Muenster, Muenster, 48149, Germany; ³A Clinical Research Unit "CATCH ALL" (KFO 5010/1) funded by the Deutsche Forschungsgemeinschaft, Kiel, Germany; ⁴Department of Medicine II, Hematology and Oncology, University Hospital Schleswig-Holstein, Kiel, 24105, Germany; ⁵Clinic for Pediatric Oncology, Hematology, Immunology, and Pneumology, Center for Pediatric and Adolescent Medicine, University Hospital Heidelberg, Heidelberg, 69120, Germany; ⁶Charité Universitätsmedizin Berlin, Department of Pediatric Oncology/Hematology, Berlin, 13353, Germany; ⁷Department of Pediatrics I, Pediatric Hematology/Oncology, ALL-BFM Study Group, Christian Albrechts University Kiel and University Hospital Schleswig-Holstein, Kiel, 24105, Germany; ⁸Department of Pediatric Hematology and Oncology, Hannover Medical School, Hannover, 30625, Germany; ⁹Institute of Medical Data Science, Otto-von-Guericke University, Magdeburg, 39120, Germany.
- 11:45 –12:00 PM** **Molecular Profiling and Its Prognostic Impact on Chinese Pediatric Patients with T-Cell Lymphoblastic Lymphoma**

Yang Li¹, Ling Jin², Yanlong Duan², Wei Liu³, Jianwen Zhou³, Fu Li⁴, Xiaomei Yang⁴, Yueping Jia⁵, Keyan Yang¹, Ying Liu⁶, Yunpeng Dai⁷, Lihua Yang⁸, Ansheng Liu⁹, Pan Wu¹⁰, Rong Liu¹¹, Lian Jiang¹², Xiaojun Yuan¹³, Jian Jiang¹⁴, Shuquan Zhuang¹⁵, Jian Wang¹⁶, Zhongjin Xu¹⁷, Hui Gao¹⁸, **Qinlong Zheng**¹, Yonghong Zhang⁶

¹Beijing Gobroad Boren Hospital, Molecular Diagnostics Laboratory, Beijing, China; ²National Center for Children's Health, Beijing Children's Hospital, Capital Medical University, Department of Hematology/Oncology, Beijing, China; ³Zhengzhou Children's Hospital, Department of Hematology/Oncology, Zhengzhou, China; ⁴Shandong University Affiliated Hospital (Jinan Children's Hospital), Department of Pediatric Hematology/Oncology, Jinan, China; ⁵Peking University People's Hospital, Department of Pediatrics, Beijing, China; ⁶Beijing Gobroad Boren Hospital, Department Of Pediatric Lymphoma, Beijing, China; ⁷Shandong Provincial Hospital Affiliated to Shandong University, Department of Pediatrics Hematology and Endocrinology, Jinan, China; ⁸Zhujiang Hospital, Southern Medical University, Department of Pediatric Hematology, Guangzhou, China; ⁹Xi'an Children's Hospital, Department of Hematologic Oncology, Xi'an, China; ¹⁰Hunan Children's Hospital, Department of Hematology, Changsha, China; ¹¹Capital institute of pediatric, Department of Hematology/Oncology, Beijing, China; ¹²The Fourth Hospital of Hebei Medical University, Department of Pediatrics, Shijiazhuang, China; ¹³Xinhua Hospital, Shanghai Jiao Tong University School of Medicine, Department of Pediatric Hematology/Oncology, Shanghai, China; ¹⁴Affiliated Hospital of Qingdao University, Department of Pediatric Hematology and Oncology, Qingdao, China; ¹⁵Quanzhou First Hospital, Fujian, Quanzhou, China; ¹⁶Anhui Provincial Children's Hospital, Department of Hematology and Oncology, Hefei, China; ¹⁷Jiangxi Provincial Children's Hospital, Nanchang, China; ¹⁸Dalian Children's Hospital, Department of Hematology, Dalian, China.

12:00 – 12:15 PM

Phase 2 NIVO-ALCL Study of Nivolumab for Relapse/Refractory ALK+ALCL, for Patients with Progressive Disease or as Consolidative Immunotherapy after Complete Remission.

Charlotte Rigaud¹, Nusaibah Ibrahim², David Sibon³, Karsten Nysom⁴, Nathalie Garnier⁵, Stéphane Ducassou⁶, Véronique Vergé⁷, Laurence Lamant⁸, Moussa Angokai², Lucie Oberic⁹, Melissa Barbati¹⁰, Mathieu Simonin¹¹, Marlène Pasquet¹², Marie-Laure Couec¹³, Sandy Amorim¹⁴, Aurélie Phulpin¹⁵, Bouabdallah Reda¹⁶, Yves Reguerre¹⁷, François-Xavier Gros¹⁸, Auke Beishuizen¹⁹, GAA Burke²⁰, Laurence Brugières¹, Anne Auperin², Véronique Minard-Colin^{1jj}

¹Department of children and adolescent oncology, Gustave Roussy cancer campus, Villejuif, France; ²Biostatistics and Epidemiology Office, Gustave Roussy, Inserm U1018 Oncostat, Ligue Contre le Cancer, University Paris-Saclay, Villejuif, France; ³Department of hematology, Henry Mondor university hospital, Créteil, France; ⁴Department of Pediatric Oncology, Copenhagen University Hospital - Rigshospitalet, Copenhagen, Denmark; ⁵Department of Pediatric Oncology, Institute for Paediatric Haematology and Oncology, Léon Bérard Center, Lyon, France; ⁶Paediatric Haematology-Oncology Department, Centre Hospitalier Universitaire (CHU), Bordeaux, France; ⁷Department of Medical Biology & Pathology, Gustave Roussy Cancer Campus, Villejuif, 94800, France; ⁸Département de cytologie et anatomie pathologiques, CHU de Toulouse, Institut universitaire du cancer Toulouse Oncopole, Toulouse, France; ⁹Department of Hematology, Oncopole - Cancer Institute of Toulouse, University Hospital of Toulouse, Toulouse, France; ¹⁰Department of Pediatric Oncology and Haematology, University Hospital of Lille, Lille; ¹¹Pediatric Hematology Oncology Department, Sorbonne Université/Trousseau Hospital, APHP, Paris, France; ¹²Department of Pediatric Oncology, Toulouse University Hospital, Toulouse, France; ¹³Pediatric Immuno-Hemato-Oncology Unit, CHU Nantes, Nantes, France; ¹⁴Service d'hémato-oncologie, hôpital Saint-Louis, AP-HP, Paris, France; ¹⁵Department of Pediatric

Hematology-Oncology, Children's Hospital of Brabois, Vandoeuvre Les Nancy, France; ¹⁶Department of Hematology, Institut Paoli-Calmettes, Marseille, France; ¹⁷Pediatric Oncology and Hematology Unit, CHU Saint Denis de la Réunion, Bellepierre, France; ¹⁸Service d'hématologie Clinique et de thérapie cellulaire, CHU de Bordeaux, Bordeaux France; ¹⁹Princess Máxima Center for Pediatric Oncology, 3584 CS Utrecht, The Netherlands; ²⁰Cancer Research UK Clinical Trials Unit (CRCTU), Institute of Cancer and Genomic Sciences, University of Birmingham, Edgbaston, Birmingham, UK.

12:15 – 12:25 PM AWARDS SESSION BEST ORAL ABSTRACT, BEST POSTER DISCUSSION ABSTRACT & BEST POSTER ABSTRACT

Award Committee

Stanton Goldman, MD, USA

Ronit Elhasid, MD, Israel

12:25 – 12:30 PM CLOSING REMARKS

Mitchell S. Cairo, MD

ABSTRACT SUBMISSION INFORMATION

ABSTRACT SUBMISSION DEADLINE Monday, June 9, 2025, 5:00 PM EST

- a) ABSTRACTS MUST BE RECEIVED BY **Monday, June 9, 2025, 5:00 PM EST** TO BE CONSIDERED FOR PRESENTATION.
- b) ABSTRACTS **MUST ADDRESS** SCIENTIFIC QUESTIONS PERTAINING TO CHILDHOOD, ADOLESCENT, OR YOUNG ADULT NON-HODGKIN LYMPHOMA or HODGKIN LYMPHOMA.
- c) ABSTRACTS WILL BE PUBLISHED in the *LEUKEMIA RESEARCH JOURNAL*
- d) ABSTRACTS ARE TO BE SUBMITTED VIA E-MAIL AS A **MICROSOFT WORD DOCUMENT ATTACHMENT** TO NHL_SYMPOSIUM@NYMC.EDU.
- e) TO PRESENT AN ABSTRACT, APPLICANT MUST BE REGISTERED TO ATTEND THE SYMPOSIUM.
- f) THERE IS NO ABSTRACT SUBMISSION FEE.
- g) YOU CAN REGISTER FOR THE SYMPOSIUM AT THE SAME TIME OF ABSTRACT SUBMISSION AT OUR WEBSITE (<http://cayanh12025.org>).

BEST ABSTRACT AWARDS

- a) BEST ORAL ABSTRACTS WILL BE SELECTED BY SCIENTIFIC MERIT FOR ORAL PRESENTATION IN EACH PLENARY SESSION OF THE MEETING. AN AWARD OF \$500 (US) WILL BE MADE FOR THE BEST ORAL PRESENTATION AT THE MEETING.
- b) ABSTRACTS OF NOTE WORTHY SCIENTIFIC MERIT WILL BE SELECTED FOR A POSTER DISCUSSION SESSION AT THE MEETING. AN AWARD OF \$500 (US) WILL BE MADE FOR THE BEST POSTER DISCUSSION PRESENTATION AT THE MEETING.
- c) ADDITIONALLY, OTHER ACCEPTED ABSTRACTS WILL BE PRESENTED IN THE GENERAL POSTER SESSION. AN AWARD OF \$500 (US) WILL BE MADE FOR THE BEST POSTER IN THE GENERAL SESSION AT THE MEETING.

ABSTRACT FORMAT

- a) ABSTRACTS MUST BE SUBMITTED VIA E-MAIL AS A **MICROSOFT WORD DOCUMENT ATTACHMENT**.
- b) ABSTRACTS SHOULD **NOT EXCEED** 400 WORDS INCLUDING TITLE AND BODY (AUTHORS' NAMES AND INSTITUTION ARE NOT COUNTED). (Limit to one figure or one table are also not counted).
- c) USE 10 PT TIMES FONT.
- d) ABSTRACT FORMAT IS AS FOLLOWS:
 - TITLE (TITLE CASE)
 - AUTHORS, INSTITUTIONS, CITY, STATE OR PROVINCE, COUNTRY
 - BODY (USE THE FOLLOWING HEADINGS):
 - BACKGROUND
 - OBJECTIVES
 - DESIGN/METHODS
 - RESULTS
 - CONCLUSION

THE FOLLOWING INFORMATION MUST BE INCLUDED IN THE E-MAIL WITH EACH SUBMISSION:

- a) NAME OF CORRESPONDING AUTHOR
- b) DEPARTMENT/INSTITUTION, CITY, COUNTRY
- c) TELEPHONE NUMBER
- d) E-MAIL ADDRESS OF CORRESPONDING AUTHOR
- e) CATEGORY DESIRED (AUTHORS MUST INDICATE THE ONE SCIENTIFIC CATEGORY)

1. MATURE B-CELL NON-HODGKIN LYMPHOMA	6. LYMPHOMA TRANSLATIONAL BIOLOGY
2. AYA NON-HODGKIN AND HODGKIN LYMPHOMA	7. NOVEL THERAPEUTICS
3. MATURE NK AND T-CELL NON-HODGKIN LYMPHOMA	8. LYMPHOBLASTIC LYMPHOMA
4. LYMPHOMA IMMUNOLOGY, HSCT & CELL THERAPY	9. BASIC AND TRANSLATIONAL BIOLOGY OF NHL & HL
5. ANAPLASTIC LARGE CELL LYMPHOMA	10. IMMUNODEFICIENCY ASSOCIATED AND OTHER RARE

- ABSTRACTS PERTINENT TO CHILDHOOD, ADOLESCENT AND YOUNG ADULT NON-HODGKIN AND HODGKIN LYMPHOMA THAT HAVE BEEN ACCEPTED/PRESENTED AT SCIENTIFIC MEETINGS WITHIN THE PAST 18 MONTHS ARE ALSO ACCEPTABLE FOR SUBMISSION TO THIS SYMPOSIUM.
- **QUESTIONS SHOULD BE ADDRESSED TO MIGUEL MUNIZ AT NHL_SYMPOSIUM@NYMC.EDU**
- **SUBMIT ABSTRACT BY E-MAIL TO: NHL_SYMPOSIUM@NYMC.EDU**

ABSTRACT REVIEW:

- a) ABSTRACTS WILL BE PEER-REVIEWED ACCORDING TO SCIENTIFIC CATEGORIES.
- b) NOTIFICATION OF ACCEPTANCE OR REJECTION OF ABSTRACTS WILL BE MADE VIA E-MAIL ON OR AROUND **JUNE 25, 2025**.
- c) THE DECISION OF THE REVIEWING COMMITTEES REGARDING THE ACCEPTANCE OF ABSTRACTS IS FINAL.

CME INFORMATION

This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education through the joint provider ship of New York Medical College and the Children's Cancer Fund, New York. New York Medical College is accredited by the ACCME to provide continuing medical education for physicians.

The New York Medical College designates this Live activity for a maximum of **21.5 AMAPRA Category 1 Credits™**. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

All activity faculty and planners participating in continuing medical education activities provided by New York Medical College are expected to disclose to the audience any significant support or substantial relationship(s) with commercial entities whose products are discussed in their presentation and/or with any commercial supporters of the activity. In addition, all faculties are expected to openly disclose any off-label, experimental, or investigational use of drugs or devices discussed in their presentation.

Have any Questions?

Contact

Ginny Davenport, RN
vdavenpo@nymc.edu

LOCATION: New York City, NY, USA

Venue Details

The InterContinental New York Times Square Hotel, 300 West 44th Street, is conveniently located with easy access to countless iconic New York City locations. Nearby are Central Park, Rockefeller Center, Broadway, the Metropolitan Museum of Art, world renowned restaurants and shopping.

Arriving in New York City and Reaching the InterContinental New York Times Square Hotel By Air

La Guardia (LGA) estimated time by taxi: 30 minutes

John F Kennedy International (JFK) estimated time by taxi: 45-60 minutes

Newark Liberty International (EWR) estimated time by taxi: 30-40 minutes; estimated time by Air Train from EWR through Penn Station: 60 minutes

By Train

Penn Station estimated time by taxi: 8 minutes

Grand Central Station estimated time by taxi: 10 minutes

Subway

42ND Street Lines A, C, E estimated walk time: 1 mile

Hotel Accommodations and Reservations

The InterContinental New York Times Square is offering the rate of \$349 + taxes for the nights of September 25, 26 and 27, 2025. To secure this rate, reservations must be made by September 2, 2025. After September 2, 2025, reservations are on availability only. **Also of note, most rooms have 2 double beds so sharing with a colleague will reduce the nightly rate to \$175/per guest. Plan to take advantage of this exceptional rate for a Midtown Manhattan hotel; rooms at this rate are limited.**

Note, under Rate Details, the amenity fee will not be applicable for those using the reservation link provided.

RESERVE ONLINE at [8th International Symposium on Childhood Adolescent and Young Adult Non-Hodgkin - Learn about the event and search for hotels \(passkey.com\)](#)

Points of Interest

Meatpacking District

Explore this trendy and historic downtown neighborhood, packed with an eclectic mix of shops, designer boutiques, restaurants, bars, night clubs and art galleries.

Chelsea

The center of the New York art world, this historic neighborhood is home art galleries, theaters, music venues and attractions like Chelsea Piers and the High Line.

Upper West Side

An upscale residential area, this neighborhood boasts several cultural destinations, including Lincoln Center and the American Museum of Natural History.

Theater District

Situated in the heart of Midtown Manhattan, this area of the city is filled with restaurants, hotels, shops, nightclubs, and historic Broadway and Off-Broadway theaters.

West Village

A funky and artsy residential and nightlife neighborhood, the West Village offers a variety of cool boutiques, coffee shops, and some of the trendiest restaurants and bars in the city.

One World Observatory

An experience unlike any other! Positioned on top of the tallest building in the Western Hemisphere, on levels 100, 101, and 102 of the 1,776-foot tall One World Trade Center building, One World Observatory provides unique panoramic views of New York City, its most iconic sites, and surrounding waters.

CONFERENCE REGISTRATION FEE INFORMATION * USD:

REGISTER ONLINE at <http://cayahl2025.org>

Registration fees can be paid by credit card or wire transfers.

Registration	By September 9, 2025	After September 9, 2025
Physicians (MD)/ Scientists (PhD)	\$ 995 USD	\$ 1295 USD
Allied Professional and Persons In-Training	\$ 695 USD	\$ 895 USD
Pharmaceutical Representative	\$ 1295 USD	\$ 1500 USD
Virtual Platform		\$ 695 USD
CME Credit		\$75 USD

US currency only

Refund Policy

50% of registration is refundable by July 26, 2025, thereafter there are no refunds.

Late and On-Site Registration (After September 9, 2025)

Attendees who register after September 9, 2025 will be charged the late/on-site registration fee. On-site registration will be located in the Gotham Park Foyer of the InterContinental Hotel starting 2:00PM, Thursday, September 25, 2025.

Meeting Cancellation Policy

The Children's Cancer Fund New York (CCF NY) and New York Medical College reserves the right to modify or cancel any or all activities associated with this meeting due to unforeseen circumstances. In the event that we have to unexpectedly cancel this meeting before July26,2025,50% of the registration fee will be returned. If the conference is cancelled after July26, 2025, there will be no refund.

In the event that 8th International Symposium on Childhood, Adolescent, and Young Adult Non-Hodgkin Lymphoma is cancelled due to Public Health Restrictions, a full refund minus 10% administration fee will be granted.

Registration Hours

Thursday, September 25, 2025 2:00 PM – 8:00 PM

Friday September 26, 2025 7:00 AM – 6:00 PM

Saturday September 27, 2025 7:00 AM – 5:00 PM

Sunday September 28, 2025 7:00 AM – 8:30 AM

SUPPORT OPPORTUNITIES

Support from philanthropic foundations and corporate under writers for this conference is welcomed and encouraged. To discuss opportunities and how you may participate, please contact Ginny Davenport@ vdavenpo@nymc.edu or Mitchell

S. Cairo, MD (Conference Chair) @mitchell_cairo@nymc.edu.



7th International NHL Symposium Faculty, New York City, NY